|
|
|
Volumn 26, Issue 1 SUPPL. 5, 1999, Pages 6-12
|
|
A phase III study of irinotecan (CPT-II) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DNA TOPOISOMERASE INHIBITOR;
FLUOROURACIL;
IRINOTECAN;
ADULT;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CANCER SURVIVAL;
CLINICAL TRIAL;
COLORECTAL CANCER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
QUALITY OF LIFE;
SURVIVAL RATE;
TREATMENT FAILURE;
TREATMENT OUTCOME;
TREATMENT PLANNING;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
CAMPTOTHECIN;
COLORECTAL NEOPLASMS;
DNA TOPOISOMERASES, TYPE I;
FEMALE;
FLUOROURACIL;
HUMANS;
MALE;
MIDDLE AGED;
NEOPLASM METASTASIS;
PALLIATIVE CARE;
PROSPECTIVE STUDIES;
QUALITY OF LIFE;
SURVIVAL ANALYSIS;
|
|
EID: 0033005770
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (72)
|
|
References (19)
|
